Lung Cancer

Lorlatinib (Lorbrena) significantly improved progression-free survival (PFS) and intracranial response rates compared with the former standard of care, crizotinib (Xalkori), as first-line treatment for patients with advanced ALK-positive non–small-cell lung cancer (NSCLC), as reported in a planned interim analysis of the CROWN trial.
Treatment with dabrafenib and trametinib produced similar benefits in pretreated and treatment-naïve patients.

[Fam-]trastuzumab deruxtecan shows promising clinical activity with a high and durable response rate in patients with HER2-mutated NSCLC.

Treatment with gefitinib in the adjuvant setting is associated with enhanced quality of life in patients with early-stage NSCLC and EGFR mutations.
Ensartinib may be a viable treatment option for some forms of secondary ALK alterations.
Similar progression-free survival and 2-year overall survival rates reported for both treatment groups, with more grade ≥3 treatment-related adverse events reported in the afatinib + cetuximab group.
Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations.
Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease.
Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums.
Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study.
Page 2 of 12
Results 11 - 20 of 111